Inhibikase Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. (ticker: IKT) is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States. It is best understood as a clinical-stage biotech story rather than a commercial pharmaceutical platform: the company’s value proposition depends primarily on the success of its pipeline, regulatory progress, and funding capacity. Founded in 2010 and publicly listed in December 2020, Inhibikase originally focused on neurodegenerative and related disorders, but in recent years it has increasingly emphasized cardiopulmonary disease, especially pulmonary arterial hypertension (PAH). At the center of the company’s strategy is a kinase-inhibition platform. Inhibikase has historically worked on Abelson tyrosine kinase (c-Abl) biology, and more recently has positioned its lead development efforts around PAH pathways involving type III receptor tyrosine kinases, including platelet-derived growth factor receptors and c-Kit. Its lead program, IkT-001, is an imatinib-based prodrug/formulation being advanced for PAH with the aim of preserving potential efficacy while improving tolerability versus prior imatinib experiences in the indication. The company’s broader scientific approach remains focused on disease-modifying mechanisms, which is important because PAH is a severe and progressive disease with a high unmet medical need. From a competitive standpoint, Inhibikase operates in a highly crowded and scientifically demanding biotech segment. It competes indirectly with specialty pulmonary hypertension companies, larger biopharma groups, and other rare-disease developers. Its differentiation lies in mechanism-driven development: the company is not simply pursuing incremental symptom management, but rather attempting to influence disease progression through targeted kinase inhibition. That can be attractive from an investor’s perspective, but it also creates significant binary risk, as clinical outcomes and regulatory interactions can materially re-rate the stock. Geographically, the company is rooted in the United States, with a long-standing operational footprint tied to Atlanta, Georgia, and research/leadership activity also associated with Boston, Massachusetts. Historically, Inhibikase described itself as headquartered in Atlanta, and more recent company materials show a Delaware corporate presence with Boston-linked operations. Recent milestones include the February 2025 acquisition of CorHepta, expansion of the PAH leadership team, a large financing in 2025, and an April 2026 inducement grant announcement under NASDAQ listing rules. For investors, IKT is a small-cap U.S. NASDAQ biotech with a focused pipeline, a clear therapeutic thesis, and meaningful execution risk tied to clinical data readouts and capital markets access.